Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.61 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | RAD52 | P43351 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.59 |
| ▸ | PAM | P19021 | 2/20 | 0.55 |
| ▸ | FABP3 | P05413 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1517489 | 1.00 | DGKA (0.71) | DGKAMAPTBLMADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL5266793 | 1.00 | DGKA (0.71) | DGKAMAPTBLMADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL5318921 | 1.00 | DGKA (0.71) | DGKAMAPTBLMADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL5317635 | 1.00 | DGKA (0.71) | DGKAMAPTBLMADRA2AADRA1A | |
| Water SCHEMBL16968729 | 0.98 | DGKA (0.69) | DGKAMAPTBLMADRA2AADRA1A | |
| SCHEMBL8385098 | 0.98 | DGKA (0.74) | DGKAMAPTBLMADRA2AADRA1A | |
| SCHEMBL198091 | 0.98 | DGKA (0.74) | DGKAMAPTBLMADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL5316150 | 0.98 | MAPT (0.70) | DGKAMAPTBLMADRA2AADRA1A | |
| SCHEMBL153530 | 0.98 | DGKA (0.74) | DGKAMAPTBLMADRA2AADRA1A | |
| SCHEMBL200400 | 0.98 | DGKA (0.74) | DGKAMAPTBLMADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719476-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2026-04-08 | — | — | EP | claimed |
| WO-2024246607-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2024-12-05 | — | — | WO | claimed |
| EP-0206947-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ESTER SALTS FOR ENHANCING GASTROINTESTINAL TRACT ABSORPTION | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| US-4973579-A | VIRICIDES | MERCK & CO., INC. (US) | 1990-11-27 | — | — | US | claimed |
| EP-0183077-B1 | PEARLESCENT HAIR-CONDITIONING AGENT | Wella Aktiengesellschaft (DE) | 1989-04-26 | — | — | EP | claimed |
| US-4822773-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1989-04-18 | — | — | US | claimed |
| EP-0206947-A2 | Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | claimed |
| EP-0183077-A1 | Pearlescent hair-conditioning agent | Wella Aktiengesellschaft (DE) | 1986-06-04 | — | — | EP | claimed |
| WO-1986002828-A1 | HAIR CONDITIONER WITH PEARLY BRILLIANTS | WELLA AKTIENGESELLSCHAFT (DE) | 1986-05-22 | — | — | WO | claimed |
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4719476-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-20250270537-A1 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
| US-12163953-B2 | P-phenylene ethynylene compounds as bioactive and detection agents | STC.UNM (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024246607-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2024-12-05 | — | — | WO | disclosed |
| US-4973579-A | VIRICIDES | MERCK & CO., INC. (US) | 1990-11-27 | — | — | US | disclosed |
| US-4822773-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1989-04-18 | — | — | US | disclosed |
| US-4729989-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0206947-A2 | Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0183077-A1 | Pearlescent hair-conditioning agent | Wella Aktiengesellschaft (DE) | 1986-06-04 | — | — | EP | disclosed |
| WO-1986002828-A1 | HAIR CONDITIONER WITH PEARLY BRILLIANTS | WELLA AKTIENGESELLSCHAFT (DE) | 1986-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12163953-B2 | P-phenylene ethynylene compounds as bioactive and detection agents | ALPG, CLPP, ANPEP | ACHE 66/4885CHRM1 4445/4885CHRM3 4380/4885 |
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SLC10A2, SLC5A7, SLC18A3 | ACHE 11/4885CHRM1 10/4885CHRM3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.